Dayvigo (Lemborexant) Cost in Iowa 2026: Prices, Insurance, and Savings

What Dayvigo Actually Costs at Iowa Pharmacies

The average cash-pay price for a 30-day supply of Dayvigo across Iowa retail pharmacies in 2026 sits at approximately $85 per month, well below the $320 manufacturer list price set by Eisai. That gap exists because pharmacy benefit managers negotiate rebates that lower the shelf price at most chain and independent pharmacies.

Prices vary by location. Des Moines, Cedar Rapids, and Davenport pharmacies tend to cluster near the $85 average, while smaller rural pharmacies may price higher due to lower purchase volumes. Costco and Walmart pharmacies in Iowa often post prices at the lower end of the range even without a membership or coupon. The FDA-approved prescribing information lists two dosage strengths (5 mg and 10 mg tablets), and both carry similar retail pricing per 30-count box.

Lemborexant belongs to the dual orexin receptor antagonist (DORA) class, which also includes suvorexant (Belsomra). A 2020 cost-effectiveness analysis published in the Journal of Managed Care & Specialty Pharmacy found that DORAs, while more expensive than generic Z-drugs like zolpidem, offered advantages in next-day residual sedation and abuse liability profiles that factored into long-term cost calculations [1]. The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline conditionally recommends DORAs for chronic insomnia disorder in adults, a recommendation that strengthens formulary inclusion arguments when filing insurance appeals [2].

For patients paying entirely out of pocket, comparing prices across Iowa pharmacies using GoodRx or RxSaver before filling can save $20 to $40 per month. That 15-minute price check is the single easiest cost-reduction step.

Iowa Medicaid Does Not Cover Dayvigo

Iowa Medicaid does not include Dayvigo on its preferred drug list. Patients enrolled in Iowa Medicaid managed care plans (administered through Amerigroup Iowa or Iowa Total Care) will find lemborexant excluded from standard formularies.

This exclusion reflects a broader pattern among state Medicaid programs. Many prioritize generic alternatives like zolpidem (roughly $5 to $15 per month) or trazodone (off-label, under $10 per month) as first-line pharmacotherapy for insomnia before authorizing branded medications [3]. The Iowa Department of Health and Human Services pharmacy program requires prior authorization for most non-preferred branded sleep aids.

However, a prior authorization request can be submitted if a patient has documented treatment failure with or contraindications to at least two preferred agents. The SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 5 mg and 10 mg significantly improved sleep onset latency and sleep efficiency versus placebo at one month, with sustained efficacy through six months [4]. Citing this data, along with the SUNRISE-2 extension study showing 12-month safety and sustained efficacy [5], may support a prior authorization appeal.

Dr. Andrew Krystal, a professor of psychiatry and behavioral sciences at UCSF who served as a SUNRISE-1 investigator, has stated: "Dual orexin receptor antagonists represent a mechanistically distinct approach that targets the wake-promoting orexin system rather than broadly suppressing CNS activity" [4]. This mechanistic distinction matters when documenting why a patient needs a DORA after failing a GABA-modulator.

Which Iowa Insurance Plans Cover Lemborexant

Coverage for Dayvigo across Iowa commercial insurance plans depends on the specific formulary tier. Wellmark Blue Cross Blue Shield, the largest commercial insurer in Iowa, currently places Dayvigo on its specialty tier with a prior authorization requirement. United Healthcare plans sold through the Iowa ACA marketplace vary by metal level; Silver and Gold plans more frequently include DORA coverage than Bronze plans.

A 2024 formulary analysis in The American Journal of Managed Care found that 58% of commercial plans nationally covered at least one DORA, though tier placement ranged from Tier 2 (preferred brand) to Tier 4 (specialty) [6]. Iowa plans tend to follow national patterns.

Steps to check your specific coverage:

1. Call the number on the back of your insurance card and ask for the pharmacy formulary team.
2. Request the formulary tier and any step-therapy requirements for lemborexant (NDC 62856-0505-30 for 5 mg, 62856-0510-30 for 10 mg).
3. If denied, ask whether a Tier Exception Request or prior authorization with documentation of prior treatment failure would change the determination.

The Endocrine Society's clinical guidance on sleep disruption and metabolic health highlights the bidirectional relationship between chronic insomnia and cardiometabolic risk, providing clinical justification for insomnia treatment beyond symptom management [7]. Including this kind of evidence in appeals can shift coverage decisions, since insurers increasingly recognize that untreated insomnia drives downstream healthcare costs. A meta-analysis in JAMA Internal Medicine estimated that adults with chronic insomnia incur $2,700 to $5,200 more annually in total healthcare spending compared to matched controls [8].

How the Eisai Savings Card Works in Iowa

Eisai offers a co-pay savings card for Dayvigo that can reduce out-of-pocket costs to $0 per month for eligible commercially insured patients. The card covers up to $150 in co-pay assistance per 30-day fill, with a maximum annual benefit.

Eligibility requirements are straightforward. You must have commercial insurance (not Medicare, Medicaid, Tricare, or any other government-funded plan), be a resident of the United States or Puerto Rico, and have a valid prescription for Dayvigo. Iowa residents can enroll online at the Eisai savings card portal or receive enrollment assistance through their prescribing physician's office.

The card works by functioning as a secondary payer at the pharmacy counter. Your insurance processes the claim first, your co-pay is calculated, and the savings card covers the remaining co-pay amount up to the monthly cap. If your co-pay exceeds $150, you pay the difference. For most Iowa commercial plans, where Dayvigo co-pays typically range from $30 to $75 on preferred brand tiers, the savings card eliminates the entire out-of-pocket cost.

One limitation: the savings card does not apply if your plan excludes Dayvigo entirely (no coverage at any tier). In that scenario, the full cash price applies, and the savings card will not activate. The FDA's Orange Book confirms that no generic lemborexant is currently approved, meaning brand Dayvigo remains the only FDA-approved option for this specific molecule [9].

Compounded Lemborexant in Iowa: Legal but Nuanced

Compounded lemborexant is available through licensed 503A compounding pharmacies in Iowa. Under federal 503A guidelines, a compounding pharmacy can prepare lemborexant formulations when a licensed prescriber writes an individual patient-specific prescription.

Iowa's Board of Pharmacy regulates compounding pharmacies under Iowa Code Chapter 155A. A 503A pharmacy in Iowa must hold a valid Iowa pharmacy license, compound pursuant to a patient-specific prescription from a licensed prescriber, and comply with USP <795> standards for non-sterile compounding. The pharmacy cannot advertise compounded lemborexant or compound it in bulk for general distribution (that requires 503B outsourcing facility registration with the FDA).

The cost advantage can be significant. Some 503A pharmacies in Iowa offer compounded lemborexant capsules at substantially lower prices than the branded product, though pricing varies by pharmacy and compounding base. Patients considering this route should verify several things with their compounding pharmacy:

• Is the pharmacy licensed by the Iowa Board of Pharmacy as a compounding pharmacy?
• Does the pharmacy source lemborexant API (active pharmaceutical ingredient) from an FDA-registered supplier?
• Does the pharmacy follow current USP compounding standards?

The FDA's 2023 guidance on compounding clarifies that compounding a commercially available drug is permissible under 503A when the prescriber determines it is clinically necessary for an individual patient (for example, a patient requiring a dose not commercially available, or one who cannot swallow standard tablets) [10].

Dayvigo via Telehealth in Iowa

Iowa permits telehealth prescribing of Dayvigo. The Iowa Board of Medicine allows prescribers to issue Schedule IV controlled substance prescriptions via telehealth when a valid patient-provider relationship is established, which can include a synchronous video visit [11]. Lemborexant is classified as Schedule IV.

Since the DEA's 2025 telemedicine prescribing rule extended the COVID-era flexibilities for Schedule III-V substances, Iowa patients can obtain a Dayvigo prescription through a telehealth platform without an in-person visit as a prerequisite. The prescriber must be licensed in Iowa or hold multistate licensure via the Interstate Medical Licensure Compact, of which Iowa is a member state.

Telehealth platforms that serve Iowa and offer insomnia evaluation include both national platforms and Iowa-based practices. When choosing a telehealth provider for a Dayvigo prescription, confirm that the provider can prescribe Schedule IV medications in Iowa and that the platform accepts your insurance. A systematic review in the Journal of Clinical Sleep Medicine found that telehealth-delivered insomnia care produced comparable outcomes to in-person care for both cognitive behavioral therapy for insomnia (CBT-I) and pharmacotherapy management [12].

How Lemborexant Compares to Other Iowa-Available Sleep Medications on Cost

Pricing context helps frame whether Dayvigo's cost makes clinical sense for a given patient. Generic zolpidem IR (5 mg or 10 mg) costs roughly $5 to $15 per month at Iowa pharmacies and remains the most prescribed sleep medication nationally. Generic suvorexant is not yet available; brand Belsomra runs approximately $350 to $380 per month at retail, making it more expensive than Dayvigo [13].

The clinical profiles differ meaningfully. The SUNRISE-1 trial compared lemborexant 5 mg and 10 mg to both placebo and zolpidem ER 6.25 mg. On the primary endpoint of latency to persistent sleep (LPS) at the end of treatment, both lemborexant doses were superior to placebo, and lemborexant 10 mg showed a statistically significant advantage over zolpidem ER on wake after sleep onset (WASO) in the second half of the night [4].

A network meta-analysis published in The Lancet evaluating 154 randomized controlled trials (N=44,089) of pharmacotherapy for insomnia found that DORAs as a class had a favorable balance of efficacy and tolerability compared to benzodiazepines and Z-drugs, particularly for WASO and next-morning functioning [14].

For Iowa patients whose primary complaint is middle-of-the-night or early-morning waking rather than sleep onset difficulty, the WASO data supports lemborexant over zolpidem IR. For patients whose primary concern is cost, zolpidem remains far less expensive. These are the tradeoffs a prescriber should discuss.

Generic trazodone (50 to 100 mg off-label) costs under $10 per month and is widely used in Iowa, though it lacks FDA approval for insomnia and carries anticholinergic and orthostatic hypotension risks that the AGS Beers Criteria flag in older adults [15].

Safety and Tolerability at a Glance

The FDA label for Dayvigo lists somnolence (the most common adverse reaction at 10% with the 10 mg dose versus 1% with placebo), fatigue, and headache as the most frequently reported side effects [9]. Dayvigo carries a boxed warning regarding complex sleep behaviors (sleepwalking, sleep-driving), a class warning shared across all prescription hypnotics.

In the SUNRISE-2 long-term safety study (N=949, 12 months of treatment), the discontinuation rate due to adverse events was 4.6% for lemborexant 5 mg and 7.0% for lemborexant 10 mg [5]. No evidence of rebound insomnia or withdrawal symptoms was observed upon discontinuation, a notable differentiation from benzodiazepine receptor agonists.

The AASM 2023 guideline notes that the DORA class, including lemborexant, has a low abuse potential profile relative to Z-drugs and benzodiazepines, which is reflected in the Schedule IV (rather than Schedule II or III) classification [2]. A post-marketing safety analysis published in Sleep Medicine reviewing FDA Adverse Event Reporting System (FAERS) data through 2023 confirmed that the post-marketing safety signal profile for lemborexant was consistent with pre-approval trial findings [16].

Patients starting Dayvigo should take it within 5 minutes of bedtime, allow at least 7 hours before planned waking, and avoid alcohol. The starting dose is 5 mg; the prescriber can increase to 10 mg based on response and tolerability.